NEUMORA THERAPEUTICS INC (NMRA) Stock Analyst Ratings
NASDAQ:NMRA • US6409791000
3.49 USD
-0.06 (-1.69%)
At close: Feb 27, 2026
3.4 USD
-0.09 (-2.58%)
After Hours: 2/27/2026, 4:30:02 PM
ChartMill assigns a Buy % Consensus number of 79% to NMRA. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 9.33. This target is 167.21% above the current price.
- NMRA was analyzed by 15 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about NMRA.
- In the previous month the buy percentage consensus was at a similar level.
- NMRA was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-17 | William Blair | Upgrade | Market Perform -> Outperform |
| 2026-01-12 | Leerink Partners | Initiate | Outperform |
| 2025-12-01 | RBC Capital | Upgrade | Sector Perform -> Outperform |
| 2025-11-17 | Stifel | Maintains | Hold -> Hold |
| 2025-10-28 | Needham | Maintains | Buy -> Buy |
| 2025-10-27 | Guggenheim | Upgrade | Neutral -> Buy |
| 2025-09-16 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2025-07-16 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-05-13 | Needham | Reiterate | Buy -> Buy |
| 2025-04-10 | Needham | Reiterate | Buy -> Buy |
| 2025-04-02 | B of A Securities | Downgrade | Buy -> Underperform |
| 2025-03-10 | Guggenheim | Downgrade | Buy -> Neutral |
| 2025-03-07 | Stifel | Downgrade | Buy -> Hold |
| 2025-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-04 | Needham | Reiterate | Buy -> Buy |
| 2025-03-04 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2025-03-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-06 | B of A Securities | Maintains | Buy -> Buy |
| 2025-01-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-02 | Needham | Reiterate | Buy -> Buy |
| 2024-12-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-22 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-11-13 | Needham | Reiterate | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-05 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2024-10-18 | Needham | Reiterate | Buy -> Buy |
| 2024-10-01 | HC Wainwright & Co. | Initiate | Buy |
| 2024-09-12 | Needham | Reiterate | Buy -> Buy |
| 2024-09-04 | RBC Capital | Reiterate | Outperform -> Outperform |
NEUMORA THERAPEUTICS INC / NMRA FAQ
Can you provide the average price target for NEUMORA THERAPEUTICS INC stock?
15 analysts have analysed NMRA and the average price target is 9.33 USD. This implies a price increase of 167.21% is expected in the next year compared to the current price of 3.49.
How do analysts rate NEUMORA THERAPEUTICS INC (NMRA)?
The consensus rating for NEUMORA THERAPEUTICS INC (NMRA) is 78.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for NMRA stock?
The number of analysts covering NEUMORA THERAPEUTICS INC (NMRA) is 15.